reinhart, is off to nevada. how much of a dampener is that? >> he's an excellent leader. he's basically going back to his old company where he had been for 30 years before he joins bayer two years ago. we're going to miss him, but it's an understandable move, i think. we are very well positioned in health care. we have a very good pharma pipeline that's picking up a lot of sales momentum. hopefully in the other areas, consumer health, we're very strong. so i do not worry about our health care business, but it's unfortunate that -- >> is there anyone scheduled to replace him? >> no. we have an interim replacement, somebody who has been with the company a long time, and until we find a good solution over time. >> you are going to get more competition this year. pfizer is coming out with a blood thinning drug. you're going to have to fight for your market share. >> yeah. well, that's the name of the game, right? we are in competition. we have a very good product. we've introduced about a year ago, so we have a little bit of a -- an early start compared to pfizer. but this is